Immunomedics awarded U.S. and Australian patents

NewsGuard 100/100 Score

Immunomedics announced that it has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.

The allowed claims cover the use of the Company's lead product, epratuzumab, which is a humanized anti-CD22 monoclonal antibody.

The claims also cover the use of anti-CD22 antibodies, alone and in combination with other therapeutics, including antibodies, cytokines, or drugs, for the treatment of major autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, vasculitis, multiple sclerosis, myasthenia gravis, diabetes mellitus, and ulcerative colitis. The Company already has received patents for the use of CD22 antibodies in the therapy of B-cell lymphomas.

"Gaining this patent protection in these two countries will further strengthen the proprietary position of our CD22 antibody, epratuzumab, as we advance its development for the treatment of autoimmune diseases such as lupus and Sjogren's syndrome, which are in clinical trials," commented Company President and CEO, Cynthia L. Sullivan.

Epratuzumab is a humanized monoclonal antibody that targets CD22 antigen, found on the surface of B-lymphocytes, a type of white blood cell. Epratuzumab is being evaluated in patients with Sjogren's syndrome and is also Immunomedics' lead product candidate in two pivotal Phase III trials for the treatment of patients with moderate and severe systemic lupus erythematosus (SLE). The FDA granted a Fast Track designation to the clinical development program for epratuzumab for the treatment of patients with SLE. Epratuzumab has also demonstrated good safety, tolerability, and clinical efficacy in more than 340 patients with non-Hodgkin's lymphoma, resulting in reports published in The Journal of Clinical Oncology and Clinical Cancer Research.

http://www.immunomedics.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits